This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
The world’s most important conference for laboratory automation and drug screening tools, SLAS 2025 International, opens today in San Diego. One of the highlights will be the pitches for the best start-up, the SLAS Ignite Award. European Biotechnology has taken a look at the technologies for you in advance.
Nippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 mutation and XIAP deficiency.
Berlin-based food tech start-up Project Eaden is prepared to launch its first plant-based ham product by mid-year in 2,000 REWE supermarkets. A oversubscribes Series A financing laid the basis for this success
Paris-based drug delivery specialist Ceres Brain Therapeutics SA has raised €6m led by ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and well-being brands, to support the clinical development neurological treatments.
Medix Biochemica Expands its Offering of Critical IVD Raw Materials to Premium Blockers and Stabilizers by Acquiring CANDOR Bioscience.
Iceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.
EuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy.
The Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare eye disease non-arteritic anterior ischaemic optic neuropathy (NAION), which leads to blindness, could occur more frequently after treatment with the GLP-1 receptor agonist.
Jena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced Acute Respiratory Distress Syndrome (ARDS).
Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections.